1.08
전일 마감가:
$1.10
열려 있는:
$1.03
하루 거래량:
24,915
Relative Volume:
0.72
시가총액:
$43.57M
수익:
$13.42M
순이익/손실:
$-73.35M
주가수익비율:
-0.5625
EPS:
-1.92
순현금흐름:
$-56.34M
1주 성능:
+65.14%
1개월 성능:
+8.01%
6개월 성능:
+9.56%
1년 성능:
-46.00%
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
명칭
Barinthus Biotherapeutics Plc Adr
전화
44 (0) 1865 818808
주소
UNIT 6-10, ZEUS BUILDING, DIDCOT
BRNS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BRNS
Barinthus Biotherapeutics Plc Adr
|
1.08 | 26.38M | 13.42M | -73.35M | -56.34M | -1.92 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-05-25 | 개시 | Jefferies | Buy |
2021-05-25 | 개시 | Morgan Stanley | Overweight |
2021-05-25 | 개시 | William Blair | Outperform |
2021-05-24 | 개시 | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr 주식(BRNS)의 최신 뉴스
BRNS stock touches 52-week low at $0.8 amid market volatility - Investing.com UK
Dollar General Corp (DG) Shares Up Despite Recent Market Volatility - The News Heater
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - MSN
Exclusive-Mexico's Pemex, billionaire Slim renegotiate deepwater gas project - Yahoo Finance
RBC raises Reckitt Benckiser stock target to £57.00, keeps outperform - MSN
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
The big rebrand: Why these 4 biopharmas changed their name this year - PharmaVoice
New trial shows promise for chronic hepatitis B treatment - Investing.com
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Mexico Shingles Vaccine Market Size & Outlook, 2023-2030 - Grand View Research
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr (BRNS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):